2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4428 Sociodemographic disparities in venetoclax-based treatment outcomes in acute myeloid leukemia patients

Sarah Marion, MD, Cristian Matic, MSPH2, Keith W. Pratz, MD3
1 Hospital of the University of Pennsylvania, Philadelphia, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, United States

Introduction

Acute myeloid leukemia (AML) has an evolving treatment paradigm with the expansion of targeted therapies and hypomethylating agent (HMA) and venetoclax-based regimens in the last decade. Many studies have explored sociodemographic disparities in AML outcomes, for which several found a persistent mortality gap between non-Hispanic Black and non-Hispanic White patients. Over time, these mortality rates and differences have lessened and a recent study by Wang et al. (Blood Adv. 2025) found a closed mortality gap between these two racial groups in the post-venetoclax era. To better understand sociodemographic patterns in this newer era, we undertook a large retrospective study examining differences in venetoclax treatment outcomes in AML patients across sociodemographic populations.

 

Methods

We performed a retrospective analysis of adults with newly diagnosed AML who received first-line venetoclax-based regimens while hospitalized at the Hospital of the University of Pennsylvania between January 2019 and December 2025. Clinical and demographic data were obtained from a shared electronic health record. Associations between race and clinical outcomes were evaluated using multivariable logistic regression adjusting for age, gender, ethnicity, and insurance type. Primary outcomes were febrile neutropenia, disseminated intravascular coagulation (DIC), intensive care unit (ICU) escalation, prolonged hospitalization (>45 days), hospital re-admission (≤30 days), early mortality (≤30 and  ≤60 days), and palliative care consultation.

 

Results

A total of 793 patients were included—mean age 67 ± 13 years; female 332 (42%), male 460 (58%), White 75% (593), Black 12% (92), other race/unknown 4% (108); not Hispanic/Latino 752 (95%), Hispanic/Latino 2.5% (20); public insurance 72% (569), private insurance 28% (224). No significant differences in the evaluated clinical outcomes were observed between Black and White patients following multivariable adjustment (febrile neutropenia OR 0.97, 95% CI 0.59 – 1.56, p=0.9; DIC OR, 1.11, 95% CI 0.63 – 2.07, p = 0.7; ICU escalation OR 1.19, 95% CI 0.58 – 2.24, p=0.6; prolonged hospitalization OR 1.74, 95% CI 0.76 – 3.64, p=0.2; 30-day readmission OR 1.03, 95% CI 0.64 – 1.64, p=0.9; 30-day mortality OR 0.97, 95% CI 0.41 – 2.03, p=0.9; 60-day mortality OR 1.22, 95% CI 0.67 – 2.13, p=0.5; palliative care consultation OR, 0.97, 95% CI 0.61 – 1.53, p=0.9).

Other race/unknown was associated with ICU escalation (OR 1.91, (1.08-3.30), p=0.022) and trended toward association with 60-day early mortality (OR 1.69, (0.99-2.81), p=0.049).

Increasing age had lower odds of prolonged hospitalization (OR 0.97, (0.95–0.99), p=0.006),  DIC (OR 0.95, (0.93–0.97), p<0.001), and palliative care consultation (OR 0.97, (0.96–0.99), p<0.001).

 

Conclusions

Our large retrospective study did not demonstrate any significant disparities in clinical outcomes between Black and White patients receiving venetoclax-based treatment for newly diagnosed AML. These findings are consistent with prior analyses that demonstrate favorable survival outcomes for Black patients receiving venetoclax, which match their white counterparts. Though not explored in our study, the drivers of this equitable impact may be more tolerated treatment profile despite comorbidities as well as underlying genetics with varying susceptibility to treatment mechanisms. However, further research is necessary to generate deeper conclusions on these evolving sociodemographic patterns.

Also in our study, other race/race unknown was associated with ICU escalation and trended towards association with 60-day mortality. This heterogeneous category is challenging to interpret though does raise suspicion that patients neither identifying as Black nor White may be vulnerable to relative suboptimal outcomes, which is supported in the literature.

Limitations included lack of multi-institutional data and therefore restricted generalizability. Socio-economic status, molecular data, and comorbidity index was not adjusted for though likely contributory as seen in the literature.  Future studies should adjust for these variables and incorporate multi-institutional data to deepen our understanding of the changing landscape of leukemia treatment and the impact on diverse patient populations.
Sarah Marion, MD: No relevant conflicts of interest to declare.